First OTC drug approved for women with overactive bladder

(HealthDay)—The drug Oxytrol has been approved by the U.S. Food and Drug Administration as the first over-the-counter treatment for women 18 and older with overactive bladder.

is characterized by symptoms including leakage, frequent urination and feeling the sudden and urgent need to urinate. The condition affects some 33 million Americans, mostly older women.

Oxytrol contains oxybutynin, among a class of drugs called anticholinergics that are designed to relax the . Oxytrol is a patch applied to the skin every four days, the FDA said in a news release.

The drug will remain available for adult men by prescription only, the agency said.

Side effects reported during clinical testing included skin irritation at the patch site, dry mouth and constipation.

Oxytrol for Women is marketed by Merck, based in Whitehouse Station, N.J.

More information: To learn more about overactive bladder, visit the U.S. Department of Health and Human Services.

add to favorites email to friend print save as pdf

Related Stories

Myrbetriq approved for overactive bladder

Jun 28, 2012

(HealthDay) -- Myrbetriq (mirabegron) has been approved to treat adults with overactive bladder, a condition affecting some 33 million Americans, the U.S. Food and Drug Administration said Thursday in a news release.

Recommended for you

Determine patient preferences by means of conjoint analysis

19 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments